CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong under the Companies Ordinance)
(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S ONCOLOGY DRUG "SKLB1028 CAPSULES" WAS GRANTED CLINICAL TRIAL APPROVAL

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries (the "**Group**")) is pleased to announce that the pre-clinical trial data of the Class 1.1 chemical drug "**SKLB1028 Capsules**" (the "**Product**") being developed by the Group has passed the technical assessment of the Centre for Drug Evaluation of China Food and Drug Administration (the "**CFDA**") of the People's Republic of China ("**China**"), and was recently granted clinical trial approval from the CFDA.

SKLB1028 is a novel multi-target protein kinase inhibitor being developed by the Group in collaboration with Sichuan University. Its major molecular targets include FLT3, EGFR, Abl, Fyn, Hck, Lck, Lyn, Ret and Yes. Pharmacology experiments at pre-clinical trial indicated exceptional inhibiting activity and good tolerance in various tumor treatments such as leukemia, non-small cell lung cancer, and in particular, acute myeloid leukemia ("AML") with FLT3-ITD mutation.

The novel molecular structure of SKLB1028 has complete intellectual property rights. The Group has applied Patent Cooperation Treaty (PCT) patent for the chemical compound of the Product in the U.S., European Union, Japan, Korea and China and authorization was already granted in China.

AML patients commonly have multiple mutations or aberrant expression of genes including FLT3, Lyn, Lck and cSrc. Approximately 30% of the AML patients have FLT3 gene mutation and approximately 20% have FLT3-ITD gene mutation. The prognosis of AML patients with FLT3-ITD mutation is in general poor with high rate of relapse.

Currently, there are several FLT3-ITD targeted small molecule drugs including quizartinib, midostaurin and lestaurtinib being developed by other overseas pharmaceutical companies, but none of these drugs have been launched in the market yet. The Group will endeavor to launch the Product in order to benefit patients with tumor in China.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 25 February 2016

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as nonexecutive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam and Mr. YU Jinming as independent non-executive directors.